Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Timing of postseed imaging influences rectal dose-volume parameters for cesium-131 prostate seed implants.

Yaparpalvi R, Hannan R, Landau E, Kahan N, Bodner W, Kuo HC, Minsky L, Mehta KJ, Garg MK, Kalnicki S, Guha C.

Brachytherapy. 2012 Nov-Dec;11(6):489-94. doi: 10.1016/j.brachy.2011.07.004. Epub 2011 Aug 24.

PMID:
21868289
2.

Dose constraint for minimizing grade 2 rectal bleeding following brachytherapy combined with external beam radiotherapy for localized prostate cancer: rectal dose-volume histogram analysis of 457 patients.

Shiraishi Y, Yorozu A, Ohashi T, Toya K, Seki S, Yoshida K, Kaneda T, Saito S, Nishiyama T, Hanada T, Shigematsu N.

Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):e127-33. doi: 10.1016/j.ijrobp.2011.01.012. Epub 2011 Mar 11.

PMID:
21398047
3.

Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis.

Snyder KM, Stock RG, Hong SM, Lo YC, Stone NN.

Int J Radiat Oncol Biol Phys. 2001 Jun 1;50(2):335-41.

PMID:
11380219
4.

Late rectal toxicity after prostate brachytherapy: influence of supplemental external beam radiation on dose-volume histogram analysis.

Kalakota K, Rakhno E, Pelizzari CA, Jani AB, Liauw SL.

Brachytherapy. 2010 Apr-Jun;9(2):131-6. doi: 10.1016/j.brachy.2009.08.012. Epub 2009 Oct 22.

PMID:
19853533
5.

Probability of late rectal morbidity in 125I prostate brachytherapy.

Waterman FM, Dicker AP.

Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):342-53.

PMID:
12527047
6.
7.

Rectal-wall dose dependence on postplan timing after permanent-seed prostate brachytherapy.

Taussky D, Yeung I, Williams T, Pearson S, McLean M, Pond G, Crook J.

Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):358-63. Epub 2006 Mar 24.

PMID:
16563654
8.

A comparative study of seed localization and dose calculation on pre- and post-implantation ultrasound and CT images for low-dose-rate prostate brachytherapy.

Ali I, Algan O, Thompson S, Sindhwani P, Herman T, Cheng CY, Ahmad S.

Phys Med Biol. 2009 Sep 21;54(18):5595-611. doi: 10.1088/0031-9155/54/18/016. Epub 2009 Aug 28.

PMID:
19717887
9.

Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy.

Corriveau J, Wallner K, Merrick G, True L, Cavanagh W, Sutlief S, Butler W.

Brachytherapy. 2003;2(2):108-13.

PMID:
15062149
10.

Influence of body mass index and periprostatic fat on rectal dosimetry in permanent seed prostate brachytherapy.

Tiberi D, Gruszczynski N, Meissner A, Delouya G, Taussky D.

Radiat Oncol. 2014 Apr 14;9(1):93. doi: 10.1186/1748-717X-9-93.

11.

AnchorSeed for the reduction of source movement in prostate brachytherapy with the Mick applicator implant technique.

Badwan HO, Shanahan AE, Adams MA, Shanahan TG, Mueller PW, Markwell SJ, Tarter TH.

Brachytherapy. 2010 Jan-Mar;9(1):23-6. doi: 10.1016/j.brachy.2009.07.002. Epub 2009 Sep 17.

PMID:
19762286
12.

Refining prostate seed brachytherapy: Comparing high-, intermediate-, and low-activity seeds for I-125 permanent seed prostate brachytherapy.

Delouya G, Bahary P, Carrier JF, Larouche RX, Hervieux Y, BĂ©liveau-Nadeau D, Donath D, Taussky D.

Brachytherapy. 2015 May-Jun;14(3):329-33. doi: 10.1016/j.brachy.2014.11.011. Epub 2015 Jan 24.

PMID:
25630619
13.

Intraoperative real-time planned conformal prostate brachytherapy: post-implantation dosimetric outcome and clinical implications.

Zelefsky MJ, Yamada Y, Cohen GN, Sharma N, Shippy AM, Fridman D, Zaider M.

Radiother Oncol. 2007 Aug;84(2):185-9. Epub 2007 Aug 10.

PMID:
17692978
14.

Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.

Vargas C, Yan D, Kestin LL, Krauss D, Lockman DM, Brabbins DS, Martinez AA.

Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):141-9.

PMID:
16111582
15.

Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.

Vargas C, Martinez A, Kestin LL, Yan D, Grills I, Brabbins DS, Lockman DM, Liang J, Gustafson GS, Chen PY, Vicini FA, Wong JW.

Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1297-308. Review.

PMID:
16029785
16.

The use of rectal balloon during the delivery of intensity modulated radiotherapy (IMRT) for prostate cancer: more than just a prostate gland immobilization device?

Teh BS, McGary JE, Dong L, Mai WY, Carpenter LS, Lu HH, Chiu JK, Woo SY, Grant WH, Butler EB.

Cancer J. 2002 Nov-Dec;8(6):476-83.

PMID:
12500857
17.

Rectal wall sparing by dosimetric effect of rectal balloon used during intensity-modulated radiation therapy (IMRT) for prostate cancer.

Teh BS, Dong L, McGary JE, Mai WY, Grant W 3rd, Butler EB.

Med Dosim. 2005 Spring;30(1):25-30.

PMID:
15749008
18.

Rectal morbidity following I-125 prostate brachytherapy in relation to dosimetry.

Ohashi T, Yorozu A, Toya K, Saito S, Momma T, Nagata H, Kosugi M.

Jpn J Clin Oncol. 2007 Feb;37(2):121-6. Epub 2007 Jan 25.

PMID:
17255159
19.

Normal tissue dosimetric comparison between HDR prostate implant boost and conformal external beam radiotherapy boost: potential for dose escalation.

Hsu IC, Pickett B, Shinohara K, Krieg R, Roach M 3rd, Phillips T.

Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):851-8.

PMID:
10705005
20.

Effect of post-implant edema on the rectal dose in prostate brachytherapy.

Waterman FM, Dicker AP.

Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):571-6.

PMID:
10524408

Supplemental Content

Support Center